AIM: To determine the maximally tolerated dose (MTD), recommended phase II dose (RPTD) and toxicity profile of gemcitabine plus irinotecan combination. PATIENTS AND METHODS: Thirty-nine evaluable patients with advanced solid tumors were treated with gemcitabine (Gem) and irinotecan (Iri) on days 1, 8 and 15 of a 28-day cycle. Dose levels included Gem/Iri 700/50, 900/50, 900/75, 500/50 mg/m(2) respectively. Dose-limiting toxicity (DLT) was assessed during cycle one; toxicity evaluation was closely monitored throughout the course of treatment. Treatment continued until disease progression or unacceptable toxicity. RESULTS: DLTs primarily consisted of grade > or = 3 thrombocytopenia lasting > or = 4 days often accompanied by grade > or = 3 neutropenia. Other grade > or = 3 toxicities included vomiting, diarrhea, fatigue and elevated alkaline phosphatase. Three patients had a partial response. Stable disease as best response was seen in 16 patients, ranging from 2-18 months. CONCLUSION: The MTD/RPTD is gemcitabine 500 mg/m(2) plus irinotecan 50 mg/m(2) on days 1, 8 and 15 of a 28-day cycle. Given the toxicity profile and negative results of phase III studies, no further testing of this treatment combination is recommended.
AIM: To determine the maximally tolerated dose (MTD), recommended phase II dose (RPTD) and toxicity profile of gemcitabine plus irinotecan combination. PATIENTS AND METHODS: Thirty-nine evaluable patients with advanced solid tumors were treated with gemcitabine (Gem) and irinotecan (Iri) on days 1, 8 and 15 of a 28-day cycle. Dose levels included Gem/Iri 700/50, 900/50, 900/75, 500/50 mg/m(2) respectively. Dose-limiting toxicity (DLT) was assessed during cycle one; toxicity evaluation was closely monitored throughout the course of treatment. Treatment continued until disease progression or unacceptable toxicity. RESULTS: DLTs primarily consisted of grade > or = 3 thrombocytopenia lasting > or = 4 days often accompanied by grade > or = 3 neutropenia. Other grade > or = 3 toxicities included vomiting, diarrhea, fatigue and elevated alkaline phosphatase. Three patients had a partial response. Stable disease as best response was seen in 16 patients, ranging from 2-18 months. CONCLUSION: The MTD/RPTD is gemcitabine 500 mg/m(2) plus irinotecan 50 mg/m(2) on days 1, 8 and 15 of a 28-day cycle. Given the toxicity profile and negative results of phase III studies, no further testing of this treatment combination is recommended.
Authors: S R Alberts; C Erlichman; J Sloan; S H Okuno; P A Burch; J Rubin; H C Pitot; R M Goldberg; A A Adjei; P J Atherton; S H Kaufmann Journal: Ann Oncol Date: 2001-05 Impact factor: 32.976
Authors: E Van Cutsem; D Cunningham; W W Ten Bokkel Huinink; C J Punt; C G Alexopoulos; L Dirix; M Symann; G H Blijham; P Cholet; G Fillet; C Van Groeningen; J M Vannetzel; F Levi; G Panagos; C Unger; J Wils; C Cote; C Blanc; P Hérait; H Bleiberg Journal: Eur J Cancer Date: 1999-01 Impact factor: 9.162
Authors: C M Rocha Lima; J R Eckardt; S S Leong; C A Sherman; J A Perkel; T Putman; A R Safa; H R Bahadori; M R Green Journal: Semin Oncol Date: 1999-10 Impact factor: 4.929
Authors: G P Stathopoulos; S K Rigatos; M A Dimopoulos; T Giannakakis; G Foutzilas; C Kouroussis; D Janninis; G Aravantinos; N Androulakis; S Agelaki; J G Stathopoulos; V Georgoulias Journal: Ann Oncol Date: 2003-03 Impact factor: 32.976
Authors: Caio Max S Rocha Lima; Diane Savarese; Howard Bruckner; Arkadiusz Dudek; John Eckardt; John Hainsworth; Furhan Yunus; Eric Lester; William Miller; Wayne Saville; Gary L Elfring; Paula K Locker; Linda D Compton; Langdon L Miller; Mark R Green Journal: J Clin Oncol Date: 2002-03-01 Impact factor: 44.544
Authors: P Rougier; E Van Cutsem; E Bajetta; N Niederle; K Possinger; R Labianca; M Navarro; R Morant; H Bleiberg; J Wils; L Awad; P Herait; C Jacques Journal: Lancet Date: 1998-10-31 Impact factor: 79.321
Authors: Caio M Rocha Lima; Mark R Green; Robert Rotche; Wilson H Miller; G Mark Jeffrey; Laura A Cisar; Adele Morganti; Nicoletta Orlando; Gabriela Gruia; Langdon L Miller Journal: J Clin Oncol Date: 2004-09-15 Impact factor: 44.544